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A diamantane derivative 1,6-Bis [4-(4-amino-3-hydroxyphenoxy) phenyl] diamantane (DPD) was found to inhibit the growth of
several cancer cell lines in the National Cancer Institute (NCI) Anticancer Drug Screen system. In this study, we examined the in vitro
and in vivo effects of DPD on human colon cancer cells. DPD exerted growth inhibitory activities in vitro against three human colon
cancer cell lines (Colo 205, HT-29, and HCT-15). DPD-treated cells were arrested at G0/G1 as analysed by flow cytometric analysis.
The expression of cyclin D was decreased in DPD-treated cells. The differentiation markers of carcinoembryonic antigen and
fibronectin were significantly increased in colon cancer cells after treatment with DPD. The epithelium-like brush borders on HT-29
cell surface were also demonstrated at 1 week after withdrawal from DPD treatment. The DPD-induced cell growth inhibition and
differentiation were irreversible after removal of DPD. The in vivo effect of tumour growth suppression by DPD was also observed in
mouse xenografts. No acute toxicity was observed after an intraperitoneal challenge of DPD in BALB/c-nude mice weekly. These
results suggest that DPD appears to be a new potentially less toxic modality of cancer therapy.
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Adamantane derivatives possess several attractive pharmacological
activities, such as antibacterial, antifungal, antiviral, and antic-
ancer effects (Aigami et al, 1975; Wang et al, 1997, 1998). Our
previous study has found that N-1-adamantylcitraconimide, N-1-
adamantylmaleimide (AMI) and N-1-diamantylmaleimide (DMI)
exhibited modest growth-inhibitory activity against four cancer
cell lines (Colo 205, HepG2, SK-BR-3, and Molt-4), and AMI and
DMI exhibited antimicrobial activity against Staphylococcus aureus
and Trichophyton mentagrophytes (Wang et al, 1997). We also
found that AMI was effective in inhibiting the growth of human
gastric cancer cells both in vitro and in vivo and induced apoptosis
in vitro (Wang et al, 1998). The AMI derivative dimethyladaman-
tylmaleimide (DMAMI) induces apoptosis and inhibits the growth
of the human colon cancer Colo205 in SCID mice (Wang et al,
2002). AMI-induced morphological changes of the cell membrane
may lead to apoptosis of SC-M1 cells (Wang et al, 1998). We
suggest that the cell membrane may be the target of adamantane.
Adamantane and diamantane are closely analogous polycyclic
alkane with the structure of three and six fused cyclohexane rings,
respectively. Although diamantane derivatives have been investi-
gated by chemists for many years, only a few studies of biological
activity on diamantane derivatives are reported (Chen et al, 1994).
In a recent study, we have characterised the anticancer activities of
diamantane derivatives using the 60 human cancer cell lines in NCI
Anticancer Drug Screen, and evaluated the structure–activity
relationship (unpublished data). 1,6-Bis[4-(4-amino-3-hydroxy-
phenoxy) phenyl] diamantane (DPD) exhibited marked anticancer
activities on the subpanel of 60 human cancer cell lines, especially
the Colo 205 (unpublished data).
O H2N
O NH2 HO
OH
For example, very strong anticancer effects of DPD were observed
against one leukaemia (HL-60), one non-small-cell lung cancer
(HOP-92), one colon cancer (Colo 205), one ovarian cancer
(OVCAR-8) and one breast cancer (T-47D) cell line with GI50
(LC50) of 0.50 (4100), 0.85 (22.3), 1.31 (6.24), 0.62 (4100) and
0.75 (4100) mM, respectively (unpublished data).
Colon cancer is a major cause of mortality in the Western world
(Giovannucci, 2002). Although chemotherapy and radiation
therapy have been attempted in either adjuvant or palliative
treatments, more effective adjuvant therapy is needed for colon
cancer patients. Nearly half of all patients with colon cancer still
die of metastatic disease after curative surgery (NIH Consensus
Conference, 1990). Therefore, developing new therapeutic drugs
for colon cancer is a worthwhile task.
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sDisordered proliferation is one of the characteristics of most of
malignant tumours. Multiple genetic alterations in tumour cells
affect the regulation of the cell cycle machinery (Hunter and Pines,
1994). Therefore, restoring normal cell cycle control in tumour
cells by using small molecule inhibitors of the cell cycle have been
considered for anticancer chemotherapy. Recent studies have
shown that the G1 phase of the cell cycle is an important period
where various signals interact to determine the proliferation,
quiescence, differentiation or apoptosis of cells (Sherr, 1994, 1996).
Cyclins A, B, D, and E undergo periodic synthesis and degradation,
thereby providing a mechanism to regulate cyclin-dependent
kinase (CDK) activity throughout the cell cycle (King and
Cidiowski, 1998). D- and E-type cyclin are expressed during G0/G1
and are referred to as start cyclins. A CDK can only be activated
once its partner cyclin has reached a critical concentration (King
and Cidiowski, 1998). The CDK2-cyclin E complex, cyclin D-
dependent kinases 4 and 6, and phosphorylated Rb are necessary for
transition from G1 to S phase (Tsai et al,1 9 9 3 ;O h t s u b oet al, 1994).
The use of chemical agents to induce differentiation of tumour
cells has received widespread attention as a potentially less toxic
cancer therapy. Human colon cancer cells exhibit different degrees
of histologic differentiation. The morphology of HT-29 cells can be
modulated to express distinct differentiation markers following
treatment with various inducers (Fantini et al, 1990; Cohen et al,
1999). The induction of differentiation in human colon cancer cells
is associated with an upregulation of production of the differentia-
tion-related molecules fibronectin (FN) and carcinoembryonic
antigen (CEA) (Drewinko et al, 1976; Brattain et al, 1984; Huang
and Chakrabarty, 1994).
New chemotherapeutic agents such as topoisomerase I inhibitor
irinotecan (CPT-11) are now used as a second-line chemother-
apeutic agent for patients who have failed to respond to previous
5-FU-based chemotherapy, but the survival remains poor for
patients with metastatic colorectal carcinoma (Cao and Rustum,
2000). In this study, we evaluated the in vitro effects of DPD on
proliferation and induction of differentiation of colon cancer cells.
In addition, we examined the in vivo activity of DPD in human
colon cancer cells Colo 205 xenografts. We have found that DPD
produced G1 arrest as a result of the inhibition of the G1 cyclin D.
In addition, DPD triggered polarisation in HT-29 cells and induced
increased expression of CEA and FN production in Colo 205, HT-
29 and HCT-15 cells. The in vivo tumorigenicity of DPD-treated
cells was significantly decreased in human colon Colo 205
xenografts. Moreover, DPD was demonstrated to have in vivo
antiproliferative effects on human colon cancer xenografts with no
obvious acute toxicity.
MATERIALS AND METHODS
Cell culture and DPD treatment
Three colon cancer cell lines Colo 205 (ATCC: CCL-222), HT-29
(ATCC:HTB-38), and HCT-15 (ATCC: CCL-225) were used in this
study. Colo 205 cells were cultured in RPMI-1640 with 10% foetal
bovine serum (Hyclone, Logan, UT, USA). HT-29 cells were
cultured in McCoys 5A with 10% foetal bovine serum and
0.01mgml
 1 gentamycin (GIBCO, Grand Island, NY, USA).
HCT-15 cells were cultured in RPMI-1640 with 20% foetal bovine
serum and 0.01mgml
 1 gentamycin. Cells were incubated in a
humidified atmosphere of 5% CO2 in air at 371C. DPD was
dissolved in DMSO at a stock concentration of 10mM and added to
culture media at a final concentration of 0.5–4mM. Cells were
seeded at 6 10
5 cells per 60mm or 1 10
6 cells per 100mm dish
in growth medium. The following day the cells were replenished
with medium containing the DPD. Cells were harvested and
counted by haemocytometer at 24, 48, and 72h after treatment
with DPD and used for further analysis.
Assessment of cell viability
At appropriate times after DPD exposure, attached cells were
trypsinised and combined with nonadherent cells. After centrifu-
gation, cells were resuspended in culture media and stained with
0.4% trypan blue, and viable cells were counted using a
haemocytometer.
DNA staining
Cycle TESTt PLUS DNA Reagent Kit (Becton Dickinson, San Jose,
CA, USA) was used for DNA staining. After washing the cells twice
with buffer solution, the cell concentration was adjusted to
1.0 10
6ml
 1 and 0.5ml of cell suspension was centrifuged at
400g for 5min at room temperature (20–251C). The cell pellet was
added on 250ml of solution A (trypsin buffer) and gently mixed.
After incubation at room temperature for 10min, 200ml of solution
B (trypsin inhibitor and RNase buffer) was added to each tube,
gently mixed and then incubated at room temperature for 10min.
This was followed by with the addition of 200ml of solution C
(propidium iodide (PI) stain solution) and incubated for 10min in
the dark on ice (2–81C). The sample was filtered through a 50-mm
nylon mesh and used for flowcytometric analysis.
Cyclin D staining
Cells were washed with 5ml of wash buffer (PBS (0.1%), NaN3
(1%), heat-inactivated foetal bovine serum), and fixed in 5ml of
1% methanol-free formaldehyde in PBS for 15min on ice. Cells
were then centrifuged at 400g for 5min and the supernatant was
discarded. Cold 75% ethanol was added drop by drop to the cell
pellet and incubated at  201C for a minimum of 2h. Just prior to
staining, ethanol was removed by centrifugation at 400g for
10min. Cold 0.25% Triton X-100 5ml wash buffer was added to the
cell pellet, vortexed and incubated for 5min on ice. A measure of
20ml of FITC-conjugated mouse anti-human cyclin D1,D 2,D 3
monoclonal antibody (clone G124-259, BD PharMingen) (Darzyn-
kiewicz et al, 1996) or isotype control antibody (mouse IgG1, clone
MOPC-21) was added to 100ml cell suspension (1 10
6 cells) and
incubated for 30min at room temperature in the dark. The cells
were washed with wash buffer, and then stained with PI solution
(10mgml
 1) for 10min. The sample was filtered through a 50-mm
nylon mesh and used for flow cytometric analysis.
Flow cytometry
Cells (20000) were analysed on a FACSCalibur flow cytometer
(Becton Dickinson) using an argon-ion laser (15mW) with the
incident beam at 488nm. The red fluorescence (PI) was collected
through a 585-nm filter and the green fluorescence (fluorescein
isothiocyanate) was collected through a 530-nm filter. The data
were analysed using ModFit and Cellquest softwares on Macintosh
computer.
FN and CEA production
Cells (1 10
6 per dish) were seeded on 10-cm dishes and allowed
to attach overnight, and then the medium was discarded and
replenished with medium containing DPD for incubation at 371C
for 3 days. The conditioned medium was collected and stored at
 201C before analysis. The levels of FN production were measured
by a quantitative enzyme-linked immunosorbent assay (ELISA,
Chemicon, USA), using primary rabbit anti-human FN antibody
and goat anti-rabbit peroxidase conjugated secondary antibody.
The levels of CEA production were measured by a radio-
immunoassay (RIA) kit (CIS Bio International, France). Both FN
and CEA concentration were normalised to nanograms per 1 10
6
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scells. The results are expressed as an average of duplicate assays
from one of two independent experiments.
Analysis of the reversibility of DPD-induced growth
inhibition of Colo 205 cells
Cells (1 10
6 per dish) were seeded on 10-cm dishes and allowed
to attach overnight and then the medium was discarded and
replenished with medium containing the DPD for incubation at
371C for 3 days. At the end of 3 days, the medium was discarded,
and the cells were replenished with fresh medium. Cells were
harvested and the cells viability were examined by haemocyt-
ometer at days 0, 3, 4 and 5 after withdrawal from 1, 2, or 4mM
DPD treatment for 72h.
Scanning electron microscopy (SEM)
The method of Cohen et al (1999) was used. Briefly, cells (1 10
6
per dish) were seeded in 10-cm dishes and allowed to attach
overnight, and then the medium was discarded and replenished
with medium containing DPD for incubation at 371C for 3 days. At
the end of 3 days the DPD was withdrawn, the cells were
replenished with fresh medium. At 1 week after DPD withdrawal,
cells were washed with PBS, then fixed with 2% glutaraldehyde in
PBS then post-fixed with 1% OsO4 in PBS, dehydrated in ethanol,
dried, coated with gold and examined in a field emission SEM
(JSM-6500F, Jeol, Japan).
In vivo analysis of the tumorigenicity of DPD-treated Colo
205 cells
All the in vivo experiments have been carried out with ethical
committee approval, and meet the standards required by the
UKCCCR Guidelines (Workman et al, 1998). The 8-week-old male
BALB/c-nu nude mice were obtained from the National Laboratory
Animal Center of National Applied Research Laboratories (Taipei,
Taiwan), and housed in a laminar flow room under sterilised
conditions with temperature maintained at 251C and light
controlled at 12h light and 12h dark cycle. The Colo 205 cells
after 1, 2, or 4mM DPD treatment for 72h were examined for
viability and transplanted subcutaneously on both side of flank
regions of nude mice. The tumour size was measured using a
vernier caliper twice a week. Tumour volume (V) was calculated
according to the following formula: V (mm
3)¼0.4AB
2, where A
and B are the longest diameter and the shortest diameter,
respectively (Attia and Weiss, 1966).
Antitumour activity of DPD in the BALB/c-nu nude mice
tumour xenograft model
Colo 205 cells were harvested and resuspended in serum-free
RPMI-1640 medium. Cells were adjusted to 1 10
7 cellsml
 1, and
inoculated in nude mice as described above. Each experimental
group included five to six mice bearing bilateral tumours. DPD was
dissolved in DMSO, treatment started when tumour size was 3–
5mm. DPD was administered via i.p. injection once a week at
doses of 18.8, 37.5 or 75mgkg
 1 (volume of injection: 0.1ml per
20g of body weight), respectively. The control group received
DMSO vehicle. Tumour size and body weight were monitored
twice a week throughout the experiment. Tumour size was
measured as described above. Drug efficacy was assessed as
tumour growth index (TGI)¼Vn/V0, where Vn is the tumour
volume of treated group on day n and V0 is the initial tumour
volume. At day 32, all mice were killed by CO2 gas. Tumours,
livers, kidneys, and lungs were collected, fixed, embedded, and
stained with haematoxylin and eosin for pathological analysis.
Enhancement of the antitumoral activity of
chemotherapeutic agent CPT-11 by DPD
Colo 205 cells were treated with DPD (4mM) or vehicle (DMSO) for
24h. Then the cells were further treated with or without CPT-11
(25mgml
 1) for another 72h. The antitumoral activities were
assayed by MTT method. The detailed procedure was reported in a
previous study (Wang et al, 1997). The cell cycle progression was
analysed as described above.
Statistics
All data are expressed as mean7s.e. The difference between
groups was assessed using Student’s t-test. A Po0.05 is considered
as significant difference.
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Figure 1 Effect of DPD on the growth of three human colon cancer cell
lines. Cells were seeded at 5 10
5 cells per 60mm or 1 10
6 cells per
100mm dish in growth medium. The following day the cells were
replenished with medium containing 1, 2, or 4mM DPD. Cells were
harvested and counted by haemocytometer. Each point represents the
mean7s.e. of triplicate cultures.
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sRESULTS
Antiproliferative effects of DPD
To determine the ability of DPD to inhibit cell proliferation in
three colon cancer cell lines, cells were incubated in the absence or
presence of increasing concentrations of DPD for 1–3 days. As
shown in Figure 1, we observed an inhibition of cell growth in
DPD-treated cells as compared with vehicle controls. Significant
growth inhibition was observed at days 2 and 3 in Colo 205 cells
and HT-29 cells after treatment with 1, 2, and 4mM DPD,
respectively. In the relatively resistant cell line HCT-15, growth
inhibition was observed after treatment with 4mM DPD at days 2
and 3.
Cell cycle analysis
The cell cycle progression of Colo205, HT-29 and HCT-15 cells was
examined using flow cytometry after exposure to 1, 2, or 4mM DPD
for 72h (Figure 2A). Figure 2B shows that majority of Colo 205
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Figure 2 The effect of DPD on cell cycle arrest at day 3 in three colon cancer cell lines. Cells were seeded at 5 10
5 cells per 60mm or 1 10
6 cells per
100mm dish in growth medium. At the following day the cells were replenished with medium containing 1, 2, or 4mM DPD. Cells were harvested and the
cell cycle was analysed by flow cytometry as described in ‘Materials and Methods’. (A) The representative cell cycle progression in DPD-treated colon cancer
cell lines. (B) The mean percentages of G0/G1, S and G2/M cells in DPD-treated colon cancer cell lines. Data are shown as the mean7s.e. of mean of
duplicate samples from one of two independent experiments.
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scells accumulated in G1 phase (87.2%) with a decrease of cells in S
phase (9.7%) after treatment with 1mM DPD for 72h. Colo205 and
HT-29 cells were mainly in G0/G1 phase (88–93%), and only a few
percent of cells in S phase (5–8%) and the G2/M phase (2.3–5%)
after exposure to 2 or 4mM DPD for 72h. The moderately increased
G0/G1,G 2/M phase and decreased S phase of HCT-15 cell
populations were observed after their exposure to 2 or 4mM DPD
for 72h. These results showed that treatment of colon cancer cells
with DPD resulted in increased G0/G1 phase with concomitant
decrease of cells in S phase.
Expression level of cyclin D in DPD-treated Colo 205 and
HT-29 cells
To further confirm the cytostatic effect induced by DPD, the
expression of cyclin D was analysed by flow cytometry. After 2mM
DPD treatment for 0–72h, the percentage of cells with expression
of cyclin D in Colo 205 and HT-29 cells decreased from 80.68 to
26.46% and 79.84 to 24.49%, respectively (Figure 3).
Induction of CEA and FN expression
Figure 4 illustrates the induction of CEA and FN production in
Colo 205, HT-29, and HCT-15 cells after DPD treatment for 72h.
DPD treatment of these cells resulted in increased secretion of CEA
(Figure 4A) and FN (Figure 4B) into the culture medium. A greater
than 10-fold increase in soluble CEA and eight-fold increase in
soluble FN/10
6 DPD-treated Colo 205 cells was seen compared to
the untreated control cells. The HT-29 and HCT-15 cells also
showed a more than three-fold increase in CEA and FN production
after treatment with DPD.
Irreversible effect of DPD-induced growth inhibition of
Colo 205
To further investigate whether the DPD-induced growth inhibition
was reversible, Colo 205 cells were treated with DPD for 72h, and
the cells were withdrawn from DPD by culturing in fresh medium
for another 120h. As shown in Figure 5A, at 72–120h after
removal of 1mM DPD from the medium the proliferation activity of
Colo 205 was reversed and returned to control level. However, no
reversal effect was observed after 2 or 4mM DPD treatment. The
viabilities of treated or nontreated cells were 90–95%, except the
cells at 120h after 4mM DPD treatment (40%) (Figure 5B).
Effect of DPD on brush border formation
To further investigate whether DPD-induced epithelium like brush
border formation in HT-29 cells. Cells were treated with 2mM DPD
for 72h, then cells were replenished with fresh culture medium and
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Figure 4 Induction of CEA (A) and FN (B) production by DPD.
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scultured for another week. Figure 6 shows that prominent brush
border formation was observed in 2mM DPD-treated cells but not
in control cells.
In vivo tumorigenicity of DPD-treated Colo 205 cells
To evaluate whether DPD-treated cells are still tumorigenic, Colo
205 cells were treated with 0, 1, 2, or 4mM DPD for 72h (cell
viability: 98.3, 98.8, 97.5, and 97.0%, respectively), and then
transplanted into BALB/c nude mice. Figure 7 shows that tumours
from control animals grew to an average size of 164mm
3 at day 32.
The tumour of DPD (1mM)-pretreated Colo 205-implanted animals
was marginally larger than control. However, tumours from 2 to
4mM DPD-pretreated Colo 205 implanted animals grew to an
average size of only 17–20mm
3. The tumour incidences were 10
out of 10 (vehicle control), nine out of 10 (1mM), four out of 10
(2mM) and two out of 10 (4mM), respectively. These results showed
that the tumorigenicity of 2–4mM DPD-treated Colo 205 cells was
significantly (Po0.01) reduced.
In vivo antiproliferation effect of DPD for human colon
cancer xenografts
We further examined whether DPD is also effective in vivo after
tumour formation. Cancer cells were transplanted into BALB/c
nude mice, and when the tumours were palpable (3–5mm), the
mice were treated either with vehicle control or DPD (18.75–
75mgkg
 1, i.p., once a week). Treatment of nude mice with DPD
(37.5–75mgkg
 1), the tumour growth index was significantly
(Po0.05) decreased in mice as compared to control groups at the
end of experiment. Figure 8A shows that tumour growth index
from control animals showed an average of 19.48 at the end of this
study. In contrast, the tumour growth index from DPD (37.5 or
75mgkg
 1)-treated animals had an average of only 4.99. The
tumour growth index of DPD (18.75mgkg
 1)-treated animals was
slightly larger than control but not statistically significant.
The challenge of DPD (18.75–75mgkg
 1, i.p., once a week) in
nude mice produced no obviously acute toxicity. No significant
reduction in body weight was found in DPD-treated mice
(Figure 8B). In addition, no tissue damage was observed in the
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Figure 5 (A) Irreversible effect of DPD-induced growth inhibition of
Colo 205. Cells were seeded at 1 10
6 cells per 100mm dish in growth
medium. The following day the cells were replenished with medium
containing 0.5, 1, 2, or 4mM DPD. Cells were harvested at days 0, 3, 4, 5
after 1, 2 or 4mM DPD treatment for 72h, then withdrawn. (B) The cell’s
viability was examined by haemocytometer. Each point represents the
mean7s.e of triplicate cultures.
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DPD 2 M 
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Figure 6 Scanning electron micrographs of HT-29 cells. Cells were
treated with 0.1% DMSO (control) or 2mM DPD for 72h, then DPD
withdrawn and replenished with fresh medium. The morphology of cells
was examined 1 week after DPD withdrawal.
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sliver, lung and kidney after examination of the tissue slices stained
with haematoxylin and eosin (data not shown).
Enhancement of the antitumoral activity of
chemotherapeutic agent CPT-11 by DPD
To further investigate whether DPD could enhance the antitumoral
activity of the chemotherapeutic agent CPT-11. Colo 205 cells were
treated with DPD or DPD in combination with CPT-11 and their
cell cycle analysed. As shown in Figure 9A, the antitumoral activity
of DPD combined with CPT-11 showed a three-fold increase in
treated cells as compared to DPD or CPT-11 alone. Figure 9B
shows that the population of sub-G0/G1 cells of DPD combined
with CPT-11 treatment group was increased (44.7%) as compared
to DPD (17.1%) or CPT-11 (18.3%) alone. These results clearly
showed that DPD enhanced the antitumoral activity of the
chemotherapeutic agent CPT-11.
DISCUSSION
We have previously found that diamantane derivatives exert strong
growth inhibitory activities in vitro against several cancer cell lines
in National Cancer Institute (NCI) Anticancer Drug Screen.
Therefore, in the current study, we evaluated the effects of DPD
in vitro and in vivo on the human colon cancer cells. To the best of
our knowledge, the present study is the first report that refers to
the in vitro cytostatic and differentiation promoting and in vivo
antiproliferative effectiveness of DPD.
In the current study, three colon cancer cell lines with distinct
biological properties (i.e. morphological differentiation, CEA
production, etc.) were used and treated with DPD. The Colo 205
is a poorly differentiated cell line, and HT-29 is a well
differentiated cell line (Kondoh et al, 1992; Laferte and Loh,
1992). The two colon cancer cell lines regardless of their state of
differentiation had their growth markedly slowed by DPD.
However, the multidrug-resistant HCT-15 (Stein et al, 1996) also
showed response to DPD. The cytostatic potency of DPD in three
cancer cell lines was heterogenous. Colo 205 and HT-29 were more
sensitive than HCT-15 in DPD-induced cell growth suppressing
and concomitant cell cycle arrest. The multidrug-resistant HCT-15
also showed different patterns of cell cycle histogram from the
Colo 205 and HT-29. In eukaryotes, the cell cycle is tightly
regulated by several protein kinases composed of a CDK subunit
and corresponding regulatory cyclin subunit, and CDK inhibitors
(Grana and Reddy, 1995; Lees, 1995). Cyclin E is a driving force in
the G0/G1-to-S phase transition in the cell cycle, and the cyclin D is
a start cyclin in cell cycle. The decrease of cyclin D in specific cell
types may signal a switch between proliferation and differentiation
(Gillett and Barnes, 1998). In the present study, we have
demonstrated that within 72h of exposure, DPD could mediate
accumulation of Colo205 and HT-29 cells in G1 phase (490%),
and the expression of cyclin D was dramatically decreased in DPD
treated cells. The data suggest that the presence of DPD is
promoting the loss of cyclin D from the cell in response to some as
yet undefined process involved in DPD-induced G0/G1 arrest and
differentiation.
Differentiation-inducing chemicals often inhibit growth in
conjunction with the induction of differentiation in cancer cells.
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Figure 7 In vivo tumorigenicity of DPD-treated Colo 205 cells. To
evaluate the in vivo antiproliferative effect of colo205 cells after 1, 2, or 4mM
DPD treatment for 72h, then withdrawal, the cell’s viability was examined
and transplanted into BALB/c nude mice and the tumour size was
measured twice a week. The viability of treated Colo 205 was greater than
95%. The tumour incidences were 10 out of 10 (control), nine out of 10
(1mM), four out of 10 (2mM), and two out of 10 (4mM), respectively. Each
data point is the mean7s.e. from 10 samples of one representative
experiment. The tumorigenicity of 2 or 4mM DPD-treated Colo 205 was
significantly (Po0.01) reduced.
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Figure 8 (A) In vivo antiproliferaive effect of DPD for human colon
cancer xenografts. When the tumours were palpable (3–5mm), the BALB/
c nude mice were either treated with vehicle control or DPD (i.p., once a
week). Each data are the mean7s.e. from six to 10 samples of one
representative experiment. Treatment of nude mice with DPD (37.5–
75mgkg
 1), the tumour growth index was significantly (Po0.05)
decreased in mice as compared to control groups. (B) Changes in body
weight of nude mice after treatment with DPD. Each data point is the
mean7s.e. from six to 10 samples of one representative experiment.
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sIn many transformed cell types, the induction of differentiation is
associated with an increase of FN expression (Reynolds et al,
1998). All-trans retinoic acid (ATRA) and sodium butyrate (NaB)
have also been shown to upregulate FN production in human colon
cancer HT-29 cells (Ohannesian et al, 1994). This study shows that
the FN production was increased by DPD in three cell lines. This
result was similar to ATRA and NaB in HT-29 cells. The Colo 205
cells, however, were relatively responsive to DPD in FN production
by comparison with the HT-29 and HCT-15. DPD induced a three-
fold increase in FN production in the HT-29 cells, which was
similar to ATRA (Niles et al, 1988).
Several studies have shown that the upregulation of CEA
expression is also associated with a differentiation induction
response in human colon cancer cells (Tanaka et al, 1990; Schroder
et al, 1998). CEA is an intracellular adhesion glycoprotein
(Toribara et al, 1989). ATRA and NaB have been reported to
enhance CEA production in some colon cancer lines (Velcich et al,
1995; Wang et al, 1999). DPD was a potent inducer of soluble CEA
production in the three cell lines, which produce CEA constitu-
tively. These results are in agreement with observations that NaB
and ATRA induced differentiation in colon cancer cells (Wang
et al, 1999). Nevertheless, NaB, at millimolar dose, induced colon
cancer cells to differentiate. However, the NaB-mediated HT29
differentiation was found to be reversible following a return to
NaB-free medium (Ophir et al, 1995). In vivo, NaB has a half-life
too short to produce any therapeutic effect. Our results show that
DPD is more active than NaB in suppressing cell growth and
concomitantly promoting differentiation of HT-29 colon cancer
cells. Differential cellular responses were observed in these three
cell lines after treatment with DPD. The differences in the cellular
responses to DPD may be due to the differences in the biological
properties of the three cell lines.
The human colon cancer cell line HT-29 offers a favourable study
system for the evaluation of various inducers involved in differentia-
tion (Fantini et al, 1990). Differentiation was characterised by
flattening of the cells, formation of brush borders (epithelium-like
structure) on apical HT-29 cell surface and tight junctions between
adjacent cells. All these morphological observations clearly indicate
that agents known to arrest cell cycle are involved in the induction of
differentiation and apoptosis in HT-29 cells (Fantini et al, 1990). In
this study, DPD-induced Colo 205 and HT-29 cell cycle arrest. These
cells differentiate to become bigger in size, less round and express
island shape, and increased adherence to one another. The DPD-
induced morphology changes are similar to forskolin in HT-29 cells
(Fantini et al, 1990), but these cells were cultured for a long-term
period (21 days) and then treated with forskolin. However, no
reversal in these morphological changes was found after withdrawal
of DPD in Colo 205 and HT-29 cells even after 120h. The brush
borders on HT-29 cell surface were also demonstrated by SEM at 1
week after DPD treatment and withdrawal. These results highlight the
important properties of irreversible differentiation effect of DPD. One
possibility is that the relatively lipophilic nature of DPD reduces
cellular efflux upon rinsing of drug-containing medium after the
initial drug exposure. The continued growth inhibitory activity may
be due to residual intracellular drug.
Treatment of Colo 205 tumour-bearing nude mice with DPD
significantly decreased the tumour growth index in mice as
compared to control groups. Moreover, once a week i.p. challenge
of DPD in nude mice produced no obvious acute toxicity. These
results together with the data that combination therapy showed
DPD could enhance the antitumoral activity of the chemotherapy
agent CPT-11 in colon cancer Colo 205 cells suggest that a G1-
targeting and differentiation-inducing agent DPD, has potential for
combination with other antineoplastic agents in treatment of
human colon cancer cells.
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